Navigation Links
InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting

Presentations include preclinical data for potential combination therapies and details of N3/4A protease sequence variations after ITMN-191 exposure

BARCELONA, Spain, April 11, 2007 /PRNewswire-FirstCall/ -- InterMune, Inc. announced today the presentation of findings from three in vitro experiments concerning its HCV protease inhibitor ITMN-191, alone or in combination with other compounds, at the 42nd Annual Meeting of the European Association for the Study of the Liver in Barcelona, Spain.

The first presentation concerned the activity of ITMN-191 alone or in combination with PEG-IFN-alfa-2a (Roche's Pegasys(R)) in an in vitro model of HCV clearance. These experiments explored the concentrations of ITMN-191 needed to achieve HCV replicon clearance from a human liver cell line during a two-week course of treatment. Complete clearance of replicon RNA was achieved with a 14-day treatment of only 45 nM of ITMN-191; a concentration well below that achieved in the liver of animal species following twice-daily oral dosing. Combination of the minimum human plasma concentration of PEG-IFN-alfa-2a with 15 nM of ITMN-191 also promoted durable replicon clearance, indicating clinical investigation of the anti-HCV activity of the two agents in combination is warranted.

The second experiment described the synergistic antiviral activity of ITMN-191 with Roche's R1479, an inhibitor of the HCV NS5B polymerase. The in vitro antiviral activity of each agent was enhanced when used in combination. Additionally, the replicon with reduced sensitivity to ITMN-191 remained fully sensitive to R1479, suggesting that the combination of these two agents could decrease the potential for the development of drug-resistant HCV variants in monotherapy treatments.

"With our continued research, we are better understanding the antiviral effects of ITMN-191, alone and in combination with other agents, such as polymerase inhibi
'"/>




Page: 1 2 3 4

Related medicine technology :

1. InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: InterMune Presents Research ITMN Hepatitis EASL Annual Meeting
(Date:7/30/2015)... 30, 2015  ResMed (NYSE: RMD ... definitive agreement to acquire Curative Medical, a ... sleep-disordered breathing medical devices and accessories. ... with ResMed,s global leadership in sleep and respiratory medicine, ... China suffering from sleep-disordered breathing ...
(Date:7/30/2015)... Calif. , July 30, 2015  EP ... /Alcon executives have recently contacted the Company about ... begin as early as Monday, August 3, 2015.  ... quoted as saying that the coming electronic contact ... of dollars over the next several years.  Novartis ...
(Date:7/30/2015)...  Amgen (NASDAQ: AMGN ) today announced ... Key results include: , Total revenues increased ... to $5,370 million, with 6 percent product sales ... Prolia ® (denosumab), Sensipar ® (cinacalcet), ... (denosumab). Unfavorable changes in foreign exchange rates impacted ...
Breaking Medicine Technology:ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23
... LIONVILLE, Pa., Dec. 16, 2010 West Pharmaceutical Services, Inc. (NYSE: ... has approved payment of the first-quarter 2011 cash dividend of $0.17 ... to shareholders of record on January 19, 2011. ... of components and systems for injectable drug delivery, including stoppers and ...
... (Nasdaq: HSKA, "Heska" or the "Company"), announced today that ... Forever, has been awarded $25,000 as the grand prize ... (Logo: http://photos.prnewswire.com/prnh/20000622/HESKALOGO) Helping low-income ... their pets for as long as possible, Pets Forever ...
Cached Medicine Technology:Heska Corporation Awards $25,000 Grand Prize to Pets Forever 2
(Date:7/31/2015)... ... 31, 2015 , ... In the most recent testosterone lawsuit news ... District of Illinois, Androgel testosterone attorneys report that a “Mini Status Conference” was held ... recording the minutes of the status conference, which was held that day, according to ...
(Date:7/31/2015)... ... July 31, 2015 , ... People love to feel ... insurance, where price is an important factor to clients when choosing to purchase ... offers the Preferred Producer Multi-Life Discount program, where advisers pass savings onto their ...
(Date:7/30/2015)... ... July 31, 2015 , ... Reduce ... or More, **Presented by FDAnews and Ginette M. Collazo, Inc.**, Sept. 16-17, 2015 ... veteran of helping drug, biologic and device firms reduce manufacturing errors by 50 ...
(Date:7/30/2015)... ... 2015 , ... As more hospitals across the country see the value in ... challenge. Because of growing competition, it is more important than ever to market ... The team at Wound Care Advantage has found that while many hospitals ...
(Date:7/30/2015)... ... July 30, 2015 , ... Women's dating ... Lines ." It's for women interested in improving their love lives using specific ... which officially launched to the public early this morning, has drawn praise from ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4Health News:Secura Consultants Gives Advisers Competitive New Edge with Multi-Life Discount Program 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 4Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2
... Steven Reinberg HealthDay Reporter , WEDNESDAY, Oct. 5 (HealthDay ... introduced the world to personal computers, then the iPod, the iPhone ... cancer. He was 56. "Apple has lost ... amazing human being," the company said in a statement it posted ...
... of strategies released today by the Commonwealth Fund Commission ... how the U.S. health care system serves vulnerable populationsthose ... of racial and ethnic minority groups. According to ... Achieve High Performance Health Care for Vulnerable Populations, closing ...
... AMHERST, Mass. -- New research based on post-hospital arrival ... adjusting for differences in injury severity, gun use, and ... assault, African-Americans have a significantly higher overall post-scene of ... by Anthony R. Harris, emeritus professor of sociology at ...
... 12 or older are estimated to have driven under the ... a 2009 National Survey on Drug Use and Health. While ... its role in causing crashes has remained in question. To ... of a car accident, researchers at Columbia University did a ...
... and run and how their knees look in an MRI ... decades in advance whether they will develop osteoarthritis, the common ... the time they reach the age of 70. Doctors ... scan and tell you definitively whether or not they will ...
... (HealthDay News) -- Technology that directly oxygenates the blood reduced ... by the H1N1 flu virus, a new British study shows. ... they noted that debate continues about the use of the ... called extracorporeal membrane oxygenation, which oxygenates the blood. It,s used ...
Cached Medicine News:Health News:Steve Jobs, Visionary Leader of Apple Inc., Dies at 56 2Health News:Steve Jobs, Visionary Leader of Apple Inc., Dies at 56 3Health News:Strategy for improving health care for uninsured, low-income, and minorities in the US 2Health News:Strategy for improving health care for uninsured, low-income, and minorities in the US 3Health News:Strategy for improving health care for uninsured, low-income, and minorities in the US 4Health News:Strategy for improving health care for uninsured, low-income, and minorities in the US 5Health News:Researchers find race disparity in post-hospital arrival homicide deaths at trauma centers 2Health News:Marijuana use may double the risk of accidents for drivers 2Health News:$6.3 million center at UCSF and UC Davis seeks ways to diagnose and prevent osteoarthritis 2Health News:$6.3 million center at UCSF and UC Davis seeks ways to diagnose and prevent osteoarthritis 3Health News:Oxygenating Blood of Hospitalized H1N1 Flu Patients Saved Lives: Study 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: